A significant and public dispute has emerged between a leading health supplement company and South Africa’s top medical regulator, leaving parents, pharmacists, and healthcare professionals in a quandary over the safety of popular children’s immune support products. The controversy centres on a safety alert issued by the South African Health Products Regulatory Authority (SAHPRA) and the forceful pushback from manufacturer Zinplex, which is now publicly questioning the scientific basis of the regulator’s stance.
The conflict began on Thursday, 8 January 2026, when SAHPRA published an official communication alerting the public and healthcare practitioners to safety concerns regarding “paediatric supplement products containing the ingredients zinc picolinate and selenium.” The regulatory body stated that these specific mineral forms, when used in supplements marketed for children, posed potential health risks that warranted a review. While not naming specific brands in the initial alert, SAHPRA advised that such products should be “removed from shelves and not administered to children” pending the outcome of a full safety review.
Zinplex’s Public Rebuttal: A Defense of Legacy and Safety
The alert sent immediate ripples through the retail and healthcare sectors, directly impacting Zinplex, a household name in South Africa for decades with its range of immune-support supplements, including its flagship children’s formulations which contain zinc picolinate.
In a robust and detailed statement released on Monday, 12 January, Zinplex CEO, Dr. Anesh Naidoo, defended the safety profile of its products. The company challenged SAHPRA’s blanket caution, framing it as premature and not sufficiently evidence-based.
“For over 30 years, Zinplex has been trusted by generations of South African families and recommended by healthcare professionals. Our formulations, including the specific chelated form of zinc we use, are backed by extensive research and a flawless record of safety,” Dr. Naidoo stated. He emphasised that the company’s products are formulated well within established international and local guidelines for paediatric daily intake levels.
The core of Zinplex’s rebuttal lies in its questioning of the specific risk cited by SAHPRA. “We have formally requested SAHPRA to provide the specific data and clinical evidence that prompted this alarming and broad-strokes alert. To date, we have not received a substantive scientific dossier that justifies the call to remove well-established, compliant products from the market,” the CEO added. The company announced it would not voluntarily recall its products and was seeking urgent clarification and engagement with the regulator.
The Dilemma for Parents and Practitioners
This public standoff has created confusion and anxiety among consumers. Zinc supplements, particularly during winter months and in the wake of recent global health crises, have become a staple in many households seeking to support children’s immune systems.
“I’ve been giving my son Zinplex for years on my paediatrician’s advice for recurrent colds,” shared Thandeka Mabaso, a mother from Centurion. “Now, one arm of the government says it’s potentially unsafe, and the company says it’s perfectly fine. Who are we supposed to believe? Do I stop immediately or carry on?”
Healthcare professionals are caught in the middle. The South African Paediatric Association (SAPA) issued a cautious interim statement, advising its members to “exercise clinical judgement” and consider pausing recommendations for the specific ingredients in question until SAHPRA provides more detailed guidance. Pharmacists report a surge in queries from concerned customers, with many opting for alternative supplements containing different forms of zinc, such as zinc gluconate or citrate, which were not mentioned in the SAHPRA alert.
Broader Implications for the Supplement Industry
The dispute highlights the often-opaque relationship between regulators and the fast-growing nutraceutical industry. Analysts suggest SAHPRA’s move may signal a broader intention to tighten oversight on complementary medicines, a category that has historically operated with less stringent pre-market scrutiny than pharmaceutical drugs.
SAHPRA, in a follow-up communication, stood by its alert, stating that its mandate is “to act proactively in the interest of public health based on emerging pharmacovigilance data” and that the review process is underway. They urged the public to heed the caution while investigations continue.
As the scientific and regulatory debate unfolds behind closed doors, the court of public opinion remains deeply divided. The outcome of this clash will not only determine the fate of a specific product line but could set a significant precedent for how children’s supplements are regulated and contested in South Africa’s complex healthcare landscape. For now, the shelves remain stocked, but consumer confidence has been visibly shaken.
About The Author
